drugset / Trial / NCT05558410

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

NCT05558410

Phase 3 Completed 1118 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of Suzetrigine (SUZ) in treating acute pain after an abdominoplasty.

Timeline

Start
2022-10-10
Primary completion
2023-08-25
Completion
2023-09-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 325 mg Oral
Subject Suzetrigine Small molecule 50 mg Oral
Comparator hydrocodone bitartrate Unknown 5 mg Oral

Indications

No indication recorded.